文献速递头颈介入US

超声引导下射频消融治疗浅表腮腺多形性腺瘤的安全性与疗效

Safety and Efficacy of Radiofrequency Ablation for Superficial Parotid Pleomorphic Adenoma.
PubMed 文献 · Korean J Radiol · 2025-01-01

回顾性比较超声引导下射频消融与腮腺切除术治疗浅表腮腺多形性腺瘤,射频消融组12例、手术组76例,倾向性评分1:1匹配后每组12例。射频消融组瘤体体积在1、3、6个月分别缩小39.7%、79.9%、88.0%,美容评分改善,总并发症率与手术组无显著差异,且手术时间、住院时间和费用均更低。

要点

  • 射频消融后瘤体体积中位数从基线2.02 cm³降至6个月0.23 cm³,体积缩小率88.0%。
  • 匹配分析中射频消融组总并发症率33.3%(4/12)与手术组41.7%(5/12)无显著差异(P=1.000)。
  • 射频消融组中位手术时间61.5分钟、住院0天、费用1859.9美元,均优于腮腺切除术。

核心结论

  • 射频消融可能成为浅表腮腺多形性腺瘤的安全有效手术替代方案,具有更短的中位手术时间、住院时间和更低费用。

研究设计与样本

  • 回顾性研究,2022年3月至2023年10月纳入88例浅表腮腺多形性腺瘤患者,射频消融组12例(平均年龄47.1岁),腮腺切除术组76例(平均年龄47.8岁),按年龄、性别、肿瘤体积、直径、位置和合并症进行1:1倾向性评分匹配。

关键影像表现/征象

  • 射频消融组瘤体体积中位数从基线2.02 cm³降至1个月1.21 cm³(P=0.015)、3个月0.53 cm³(P=0.002)、6个月0.23 cm³(P=0.003)。
  • 射频消融组1、3、6个月体积缩小率分别为39.7%、79.9%、88.0%。
  • 射频消融组美容评分(0-4分)在3个月和6个月随访时中位数均为1分,低于基线的4分(P=0.04)。
  • 射频消融组数值评定量表评分(0-10分)在整个随访期间与基线无显著差异。

诊断标准与关键数值

  • 射频消融组与手术组匹配后各12例,射频消融组中位手术时间61.5分钟 vs 手术组253.3分钟(P<0.001)。
  • 射频消融组中位住院时间0天 vs 手术组4天(P<0.001)。
  • 射频消融组费用1859.9美元 vs 手术组3512.4美元(P<0.001)。
  • 射频消融组总并发症率33.3%(4/12) vs 手术组41.7%(5/12),P=1.000,无显著差异。

临床应用与阅片要点

  • 对浅表腮腺多形性腺瘤,超声引导下射频消融可作为手术替代选择,需评估瘤体体积变化和并发症。
  • 射频消融后应随访瘤体体积缩小情况,1、3、6个月体积缩小率分别为39.7%、79.9%、88.0%。
  • 美容评分在射频消融后3个月和6个月改善,数值评定量表评分无显著变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To retrospectively compare the safety and efficacy of ultrasound-guided radiofrequency ablation (RFA) with parotidectomy for superficial pleomorphic adenoma (PA).

MATERIALS AND METHODS: From March 2022 to October 2023, 88 patients diagnosed with superficial parotid PA underwent either RFA (n = 12; mean age, 47.1 years) or parotidectomy (n = 76; mean age, 47.8 years). Patients in the RFA group were matched to those in the surgery group in a 1:1 ratio using propensity scores based on age, sex, tumor volume, diameter, location, and comorbidities. Ultrasound characteristics, cosmetic scores (0-4), numerical rating scale scores (0-10), and complications were assessed before the procedures and at 1-, 3-, and 6-month follow-ups. Outcomes were compared between baseline and follow-up in the RFA group and between the RFA and surgery groups.

RESULTS: In the RFA group, significant reductions in tumor volume were observed between baseline (median, 2.02 cm³) and the 1-month follow-up (median, 1.21 cm³; P = 0.015), between the 1-month and 3-month follow-ups (median, 0.53 cm³; P = 0.002), and between the 3- and 6-month follow-ups (median, 0.23 cm³; P = 0.003). The volume reduction ratios at 1, 3, and 6 months were 39.7%, 79.9%, and 88.0%, respectively. The cosmetic score was significantly lower at 3- and 6-month follow-up compared to baseline (median 1 and 1 vs. 4, P = 0.04). The numerical rating scale scores did not differ significantly from baseline throughout follow-up. In the propensity score-matched analysis (12 patients per group), RFA was associated with a shorter median procedure time (61.5 vs. 253.3 minutes; P < 0.001), shorter hospital stay (0 vs. 4 days; P < 0.001), and lower cost (1859.9 vs. 3512.4 USD; P < 0.001) than parotidectomy, with no significant difference in overall complication rates (33.3% [4/12] vs. 41.7% [5/12]; P = 1.000).

CONCLUSION: RFA may be a safe and effective alternative to surgery for superficial parotid PA, offering a shorter median procedure time, shorter hospital stay, and lower costs.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Lee CY, Lin WC, Luo SD, et al. Safety and Efficacy of Radiofrequency Ablation for Superficial Parotid Pleomorphic Adenoma. Korean J Radiol. 2025. PMID: 40307200. doi:10.3348/kjr.2024.0909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。